The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and TB-500 Thymosin Beta-4. It critiques the credibility of biohacking claims.
Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.
Microneedling stimulates hair growth through stem cell activation during wound healing, not just increased blood flow. Other methods like showers or supplements don't replicate this effect.
Low oxytocin levels in hair are linked to reduced empathy and may affect hair growth. Cinnamic acid can promote hair growth by activating oxytocin receptors.
KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.
Fatty liver and related issues may influence hair loss conditions like Dupa/Aga. Treatments discussed include Minoxidil, finasteride, RU58841, myo-inositol, and L-glutamine.
PP405 may revive dormant hair follicles, and DHT blockers like finasteride or dutasteride could maintain new hair. Combining PP405 with minoxidil might be optimal, but long-term effects and continuous use are uncertain.
GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.
The user is experiencing sudden hair loss and is considering micro-needling, low-level light therapy, iron supplements, folihair, and Omega 3. They are hesitant to start finasteride, suspecting the hair loss might be due to telogen effluvium from a past COVID-19 infection.
The conversation discusses various theories of hair loss, including DHT sensitivity and genetic factors, with the user willing to use themselves for research due to having a hair loss gene but different hair loss patterns compared to their brothers. Specific treatments were not mentioned in the provided text.
PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hair follicles, potentially offering a long-term solution, though not a permanent cure.
A user is seeking advice on increasing graft survivability after a hair transplant, mentioning PRP, Mesotherapy, Stem Cell injections, and considering L-Arginine before starting Minoxidil. They are looking for ways to support blood flow before applying Minoxidil.
A 37-year-old man is seeking advice for hair loss treatment, considering options like finasteride and topical or oral minoxidil. A user suggests consulting a doctor and monitoring blood pressure if using oral minoxidil.
HMI-115, a potential treatment for hair loss that has been reported to produce significant regrowth in bald areas. It is the closest thing to a cure currently available and has raised hope that it could make hair transplants obsolete.
JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.
Deoxyribose sugar gel may stimulate hair regrowth similarly to minoxidil by enhancing blood supply and follicle activity. Human trials are necessary, and current products have mixed results.
A 25-year-old who has been using minoxidil and finasteride for 4 years to treat hair loss, underwent a successful FUE hair transplant in Mumbai, India, in April 2023. The user reported positive results, including increased hair density and reduced frizziness, and plans to continue treatment for further growth.
A 23-year-old male experienced hair thinning and side effects from finasteride and minoxidil. He found improvement in hair health and other symptoms by using mouth tape at night, suggesting better oxygen intake might help with hair loss.
People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.
The user experienced an elevated heart rate from using topical Minoxidil and discontinued its use. They found that adding a daily protein shake helped with telogen effluvium.
The user has tried topical Minoxidil and oral Minoxidil for beard and scalp hair growth with minimal results, and has been on Finasteride for 7 months with stabilized scalp hair but no facial hair improvement. They are considering using a SULT1A1 enzyme booster to enhance results and are questioning its effectiveness without concurrent topical Minoxidil application.
PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.
The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.